AHA Press Release
  • Cardioviva™ American Heart Association Press Release

  • Study Highlights:

  • A new probiotic lowered LDL “bad” cholesterol and total cholesterol in patients with high cholesterol.
  • The probiotic supported reduction of molecules known as cholesterol ester saturated fatty acids, which have been tied to dangerous plaque buildup in the arteries.

  • Read more

News
  • 20 Nov 2013

  • -

  • 12 Nov 2013

  • -

  • 27 July 2013

  • -

  • 16 July 2013

  • -

  • 14 June 2013

  • -

  • 12 June 2013

  • -

  • 3 June 2013

  • -

  • 3 June 2013

  • -

  • 14 May 2013

  • -

  • 15 April 2013

  • -

  • 11 April 2013

  • -

  • 5 April 2013

  • -

  • 1 April 2013

  • -

  • 28 March 2013

  • -

  • 12 March 2013

  • -

  • 26 Nov 2012

  • -

  • 5 Nov 2012

  • -

  • Cardioviva™ American Heart Association Press Release

  • Study Highlights:

  • A new probiotic lowered LDL “bad” cholesterol and total cholesterol in patients with high cholesterol.
  • The probiotic altered the amount of molecules known as cholesterol ester saturated fatty acids, which have been tied to dangerous plaque buildup in the arteries.

  • Read more
  • 16 October 2012

  • -

  • Cardioviva™ will help fill the gap between diet, exercise and drugs

  • Montréal, Québec, Oct. 11, 2012 – Over half (52 percent) of supplement users are concerned about their heart health and 73 percent express an interest in natural, clinically proven solutions for healthy cholesterol support, according to market research conducted by Micropharma Limited, a pioneer in the development of innovative and effective probiotics.


    Read more
  • 19 September 2012

  • -

  • Micropharma Limited Expedites Patent Portfolio to Protect Unique Probiotic Technology including Cardioviva™

  • Micropharma Limited, a pioneer in the development of innovative and effective probiotics, has filed a number of patents for its probiotic technologies. Probiotics - bacteria that confer a health benefit to the host - are being studied to determine if they may have a more significant role in helping to maintain and improve health and wellness through the gut. And emerging science is evaluating whether supplementing the microbiome (gut bacteria) with probiotics can play a role in health and certain chronic diseases such as heart disease.


    Read more
  • 19 September 2012

  • -

  • Cardioviva™ supports healthy cholesterol and inflammatory markers in a randomized controlled trial

  • Montréal, Québec - Micropharma Limited, a pioneer in the development of innovative and effective probiotics, released the results today of a second gold standard clinical trial evaluating the efficacy of Cardioviva™. The study was aimed at evaluating the cholesterol-lowering efficacy and the mechanism of action of Lactobacillus reuteri NCIMB 30242 (Cardioviva™) capsules in hypercholesterolemic adults. A total of 127 subjects completed a randomized, double-blind, placebo-controlled, parallel-arm, multicenter study.


    Read more
  • 14 September 2012

  • -

  • Cardioviva™ is the subject of an article on usprobiotic.org regarding an update on cholesterol lowering probiotics

  • Montreal, Quebec - In a recent article written by Dr. Mary Ellen Sanders entitled: Update on Cholesterol-Lowering Probiotics published on usprobiotics.org, Dr. Sanders writes "...until recently, there has not been many convincing randomized, controlled trials that document specific probiotic-induced improvements in blood lipids. A recent study suggests that certain probiotics might improve blood lipid profiles. Jones et al. 2012 testes the effect of feeding hypercholesterolemic adults yogurt containing microencapsulated Lactobacillus reuteri NCIMB 30242. A total of 114 subjects, divided between probiotic and placebo group, participated in this study.


    Read more
Publications
  • 19 September 2012

  • -

  • 25 April 2012

  • -

  • 15 March 2012

  • -